Friday at 1:33 p.m.
Filed under:
Pharmaceuticals
By Reuters
Pfizer Inc. said on Friday its experimental rheumatoid arthritis drug met most of the main goals of a late-stage clinical trial.
If approved, it would compete with injectable treatments such as Humira, made by Abbott Laboratories, Amgen Inc.’s Enbrel, and Remicade, made by Johnson & Johnson. Get the full story »
March 24 at 1:14 p.m.
Filed under:
Pharmaceuticals
By Reuters
Abbott Laboratories and its top selling rheumatoid arthritis drug Humira are strong enough to withstand looming competition from a new pill developed by Pfizer Inc., analysts say, despite investor fears that have hobbled Abbott’s shares. Get the full story »